Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CRESTOR · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CRESTOR | DRUG | - |
Inclusion Criteria: * Chronic symptomatic systolic heart failure of ischaemic aetiology as judged by the investigator, optimal therapy for chronic symptomatic systolic heart failure according to the investigator Exclusion Criteria: * Acute myocardial infarction within 6 months before randomizatio...
Top 20 of 31 competitors
CRESTOR is a small molecule being studied for heart failure. It is an investigational treatment evaluated in a Phase 3 clinical trial in patients with heart failure. The study compared CRESTOR to placebo in subjects with heart failure, with a total enrollment of 5,013 participants.
CRESTOR is developed by AstraZeneca PLC, a biopharmaceutical company listed on the stock exchange under the ticker AZN. AstraZeneca is conducting clinical research to evaluate CRESTOR for the treatment of heart failure.
CRESTOR is in Phase 3 clinical development for heart failure. It is an investigational drug, meaning it has not been approved for this use and is still being studied in clinical trials. One Phase 3 trial has been completed.
CRESTOR has one completed Phase 3 clinical trial, identified as NCT00206310, titled "Crestor Versus Placebo in Subjects With Heart Failure." The trial enrolled 5,013 participants and was conducted in multiple countries including Belgium, France, Germany, Spain, the United Kingdom, and the United States.
CRESTOR is a brand name for rosuvastatin, a medication in the statin class. In the context of heart failure, it is being studied as an investigational treatment. The clinical trial NCT00206310 evaluated CRESTOR versus placebo in subjects with heart failure.